Address
Email address
Phone number
https://icosagen.eeKoduleht - IcosagenMuudame ideed reaalsuseks Icosagen on pühendunud Eesti biotehnoloogiaettevõte, mis tegeleb terapeutiliste antikehade arendamise ja diagnostiliste rekombinantsete valkude tootmisega imetajate rakkudes nii teadusuuringute kui ka in vitro diagnostika tarbeks. Loe lisaks Meist Teenused Klientide tagasiside “Fast responses, great flexibility, transparency, collaborative spirit, high quality” Ridgeline Kliki siia”Fast reply, quality of reports, good product profile” Pharis Biofarmaceuticals […]
Name
Icosagen Cell Factory OÜ
Registry code
11107818
VAT number
EE100969520
Type
OÜ - Limited Liability Company
Status
Registered
Foundation date
15.04.2005 (19)
Financial year
01.01-31.12
Capital
11 504.00 €
Activity
96099 - Other service activities 72111 - Research and experimental development on biotechnology
13 347 905 €
2 475 854 €
19%
3 027 €
(estimate is approximate)
17 655 397 €
134
Submitted
No tax arrears
14%
10%
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Icosagen AS 10565884 | 100% - 11 504.00 EUR | - | - | Founder |
| Mart Ustav 16.07.1949 (75) | - | Board member | Indirect ownership | |
| Ene Talpsep 25.03.1953 (71) | - | - | Member of a higher management body, i.e. board member or supervisory board member |
| 2019 16.06.2020 | 2020 29.06.2021 | 2021 17.06.2022 | 2022 11.05.2023 | 2023 11.06.2024 | |
|---|---|---|---|---|---|
| Total Revenue | 4 767 928 € | 6 679 291 € | 11 485 743 € | 13 677 072 € | 13 347 905 € |
| Net profit (loss) for the period | 704 429 € | 1 743 876 € | 5 332 983 € | 5 967 760 € | 2 475 854 € |
| Profit Margin | 15% | 26% | 46% | 44% | 19% |
| Current Assets | 2 374 310 € | 3 931 706 € | 9 313 303 € | 12 870 969 € | 6 572 660 € |
| Fixed Assets | 1 400 765 € | 1 861 668 € | 2 370 529 € | 6 741 209 € | 17 155 320 € |
| Total Assets | 3 775 075 € | 5 793 374 € | 11 683 832 € | 19 612 178 € | 23 727 980 € |
| Current Liabilities | 899 155 € | 1 163 024 € | 1 919 486 € | 3 453 448 € | 5 663 753 € |
| Non Current Liabilities | 740 996 € | 751 550 € | 552 563 € | 979 187 € | 408 830 € |
| Total Liabilities | 1 640 151 € | 1 914 574 € | 2 472 049 € | 4 432 635 € | 6 072 583 € |
| Share Capital | - | - | - | - | - |
| Equity | 2 134 924 € | 3 878 800 € | 9 211 783 € | 15 179 543 € | 17 655 397 € |
| Employees | 44 | 50 | 67 | 102 | 134 |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q1 | 5 879 468.08 € | 801 430.74 € | 852 031.05 € | 170 |
| 2023 Q4 | 7 583 415.26 € | 569 188.6 € | 599 327.99 € | 157 |
| 2023 Q3 | 4 758 860.94 € | 551 505.34 € | 588 217.7 € | 149 |
| 2023 Q2 | 4 708 061.84 € | 577 252.37 € | 538 385.13 € | 140 |
| 2023 Q1 | 5 568 859.88 € | 604 233.36 € | 640 958.12 € | 134 |
| 2022 Q4 | 4 133 717.78 € | 399 992.08 € | 423 702.82 € | 120 |
| 2022 Q3 | 3 938 823.9 € | 391 344.1 € | 414 444.95 € | 116 |
| 2022 Q2 | 3 935 976.25 € | 373 635.94 € | 349 547.68 € | 108 |
| 2022 Q1 | 4 108 645.21 € | 365 681.52 € | 389 742.73 € | 94 |
| 2021 Q4 | 3 522 064.92 € | 314 246.79 € | 278 224.69 € | 81 |
| 2021 Q3 | 3 125 232.28 € | 316 809.51 € | 248 623.61 € | 78 |
| 2021 Q2 | 3 634 670.1 € | 288 561.78 € | 214 604.94 € | 75 |
| 2021 Q1 | 1 816 063.77 € | 260 152.2 € | 278 588.13 € | 68 |
| 2020 Q4 | 1 924 413.72 € | 169 814.31 € | 181 998.61 € | 61 |
| 2020 Q3 | 2 058 958.93 € | 179 653.7 € | 177 857.55 € | 56 |
| 2020 Q2 | 1 933 445.94 € | 152 755.64 € | 163 358.79 € | 50 |
| 2020 Q1 | 1 350 643.04 € | 196 597.52 € | 202 182.38 € | 50 |
